Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02272998
Title Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Sameek Roychowdhury
Indications

hematologic cancer

Advanced Solid Tumor

Therapies

Ponatinib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST